drugset / Trial / NCT03824704
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Phase 2
Terminated
1 enrolled
pharmaand GmbH
Bristol-Myers Squibb · collabFoundation Medicine · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometroid ovarian cancer. Patients entering the following cohorts must have BRCA mutational status confirmed by a central lab: * Cohort A1: No BRCA mutation in tumor; high level of LOH (loss of heterozygosity) * Cohort A2: BRCA mutation in tumor
Timeline
- Start
- 2019-08-23
- Primary completion
- 2020-08-24
- Completion
- 2020-08-24
Outcome
Outcome not reported
Stopped (Enrollment): “Sponsor made a business decision to discontinue the study due to low accrual.”